SCHEMBL10200281

SCHEMBL10200281

COc1ccc2c(c1F)C(=O)OC2

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.69
KDM4E B2RXH2 3/20 0.69
CYP3A4 P08684 1/20 0.47
HTT P42858 5/20 0.45
MAPT P10636 5/20 0.45
GAA P10253 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
CYP19A1 P11511 3/20 0.42
PDE5A O76074 1/20 0.41
PDE4A P27815 1/20 0.41
PDE1A P54750 1/20 0.41
PDE1B Q01064 1/20 0.41
PDE4B Q07343 1/20 0.41
PDE4C Q08493 1/20 0.41
PDE4D Q08499 1/20 0.41
PDE3B Q13370 1/20 0.41
PDE1C Q14123 1/20 0.41
PDE3A Q14432 1/20 0.41
HPGD P15428 1/20 0.41
MAPK1 P28482 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30294185 0.81 KDM4E (1.00) LMNAKDM4ECYP3A4HTTMAPT
SCHEMBL698750 0.81 KDM4E (1.00) LMNAKDM4ECYP3A4HTTMAPT
SCHEMBL31619335 0.80 KDM4E (0.69) LMNAKDM4ECYP3A4HTTMAPT
SCHEMBL15902735 0.80 KDM4E (0.69) LMNAKDM4ECYP3A4HTTMAPT
SCHEMBL1029836 0.79 KDM4E (0.67) LMNAKDM4ECYP3A4HTTMAPT
SCHEMBL2338034 0.78 KDM4E (0.42) LMNAKDM4ECYP3A4HTTMAPT
SCHEMBL5467018 0.77 KDM4E (0.46) LMNAKDM4EMAPTGAASMN1; SMN2
SCHEMBL20231727 0.75 CYP3A4 (0.53) LMNAKDM4ECYP3A4HTTMAPT
SCHEMBL27091762 0.74 KDM4E (0.44) LMNAKDM4EMAPTGAASMN1; SMN2
SCHEMBL26728820 0.73 KDM4E (0.48) LMNAKDM4EHTTMAPTGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8569336-B2 Compounds for the treatment of inflammatory disorders TONG LING (US) 2013-10-29 US disclosed
US-8569336-B2 Compounds for the treatment of inflammatory disorders TONG LING (US) 2013-10-29 US disclosed
US-20120015926-A1 COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS TONG LING (US) 2012-01-19 US disclosed
US-20120015926-A1 COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS TONG LING (US) 2012-01-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120015926-A1 COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS TNF, ADAMTS1, ADAMTS7 LMNA 1280/4885KDM4E 4592/4885CYP3A4 2754/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.